Results 121 to 130 of about 73,095 (214)

Targeting the DNA Damage Response in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Targeting the DNA damage response (DDR) reshapes both tumor vulnerability and antitumor immunity. DNA lesions and DDR inhibitors can promote cytosolic nucleic‐acid sensing, antigen presentation, and immune activation, but can also induce adaptive immune escape.
Yihuan Qiao   +4 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

open access: yesThe Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi   +8 more
wiley   +1 more source

Relating transcriptomics to protein abundance reveals self‐driven versus interactor‐driven proteins

open access: yesProtein Science, Volume 35, Issue 10, October 2026.
Abstract Statistically modeling the interdependence between transcriptomics and protein abundances remains a persistent challenge in bioinformatics research. Transcriptomic data and proteomic abundances typically display a moderate Pearson's correlation of about 0.5, while in tumor conditions, the correlation may decrease to a much weaker correlation ...
Loulwah Arnaout   +2 more
wiley   +1 more source

Relaxin‐2: Shaping the Proteomic Landscape of Skeletal Muscle Physiology, Glucose Trafficking, and Mitochondrial Function in Rat

open access: yesThe FASEB Journal, Volume 40, Issue 18, 30 September 2026.
Cardioprotective hormone relaxin‐2 showed relevant effects on rat skeletal muscle by altering proteins linked to muscle function, regeneration, differentiation, mitochondrial function, glucose metabolism, and structural integrity and organization. Specifically, relaxin‐2 reduced the expression of 95 proteins, increased 32, and elicited unique proteins ...
Xocas Vázquez‐Abuín   +11 more
wiley   +1 more source

The evolving role of immunotherapy in ovarian cancer

open access: yesCancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani   +2 more
wiley   +1 more source

(S)‐Pyrrolo[1,2‐a]pyrazine‐3‐carboxamide Analogs as Dual Akt/JNK Modulators With Antiproliferative Effects in MDA‐MB‐468 Cells

open access: yesChemMedChem, Volume 21, Issue 17, 14 September 2026.
Among 30 synthesized pyrrolo[1,2‐a]pyrazine analogs, compounds B1 and B3 showed strong and selective cytotoxicity toward TNBC cells, inducing apoptosis through Akt suppression and JNK activation. Triple‐negative breast cancer (TNBC) remains a major clinical challenge due to the absence of effective targeted therapies.
Narges Hosseininasab   +10 more
wiley   +1 more source

Comprehensive Genomic Profiling Reveals the Mutational Spectrum and Clinical Significance of BRCA1/2 and Other Cancer-Susceptibility Genes in Breast Cancer Patients from Southern Tunisia. [PDF]

open access: yesCancers (Basel)
Ammous-Boukhris N   +11 more
europepmc   +1 more source

Precision Chemistry for Protein Lysine Modification

open access: yesChemistry – A European Journal, Volume 32, Issue 34, 11 September 2026.
Selective modification of lysine residues is challenging due to their similar intrinsic reactivity. Inspired by enzymatic recognition, ligand‐guided electrophiles enable site‐selective labeling and functionalization, while ligand‐guided catalyses achieve regioselective installation of bio‐relevant post‐translational modifications.
Mayu Onoda, Motomu Kanai
wiley   +1 more source

Home - About - Disclaimer - Privacy